These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 31161538)

  • 41. Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
    Benjamin DJ; Hsu R
    Front Immunol; 2023; 14():1258388. PubMed ID: 37675102
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
    Necchi A; Ramlau R; Falcón González A; Chaudhry A; Todenhöfer T; Tahbaz R; Fontana E; Giannatempo P; Deville JL; Pouessel D; Yoon S; Powles T; Bernat M; Häckl M; Marszewska M; McKernan P; Saulay M; Scaleia F; Engelhardt M; Loriot Y; Siefker-Radtke A; De Santis M
    JNCI Cancer Spectr; 2024 Apr; 8(3):. PubMed ID: 38627238
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Erdafitinib exerts the anticancer effect on urothelial carcinoma
    Jin YY; Tong SQ; Tong M
    Pharmazie; 2020 May; 75(5):195-197. PubMed ID: 32393427
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
    Roskoski R
    Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FDA Approves First Agent to Treat Locally Advanced, Metastatic Urothelial Cancer.
    Kahl KL
    Oncology (Williston Park); 2020 Jan; 34(1):11. PubMed ID: 32645199
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer.
    Nauseef JT; Villamar DM; Lebenthal J; Vlachostergios PJ; Tagawa ST
    Expert Opin Pharmacother; 2020 Jun; 21(8):863-870. PubMed ID: 32124650
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue.
    Rizzo A; Ricci AD; Frega G; Di Federico A; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):567-574. PubMed ID: 33787429
    [No Abstract]   [Full Text] [Related]  

  • 48. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
    Tyulyandina A; Harrison D; Yin W; Stepanova E; Kochenkov D; Solomko E; Peretolchina N; Daeyaert F; Joos JB; Van Aken K; Byakhov M; Gavrilova E; Tjulandin S; Tsimafeyeu I
    Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3).
    Yamani A; Zdżalik-Bielecka D; Lipner J; Stańczak A; Piórkowska N; Stańczak PS; Olejkowska P; Hucz-Kalitowska J; Magdycz M; Dzwonek K; Dubiel K; Lamparska-Przybysz M; Popiel D; Pieczykolan J; Wieczorek M
    Eur J Med Chem; 2021 Jan; 210():112990. PubMed ID: 33199155
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.
    Morales-Barrera R; Suárez C; de Castro AM; Racca F; Valverde C; Maldonado X; Bastaros JM; Morote J; Carles J
    Cancer Treat Rev; 2016 Nov; 50():208-216. PubMed ID: 27743530
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Re: Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
    Chang SS
    J Urol; 2020 Feb; 203(2):251. PubMed ID: 31710554
    [No Abstract]   [Full Text] [Related]  

  • 52. Fibroblast growth factor receptor inhibitors: patent review (2015-2019).
    Marseglia G; Lodola A; Mor M; Castelli R
    Expert Opin Ther Pat; 2019 Dec; 29(12):965-977. PubMed ID: 31679402
    [No Abstract]   [Full Text] [Related]  

  • 53. VEGF inhibition in urothelial cancer: the past, present and future.
    Ghafouri S; Burkenroad A; Pantuck M; Almomani B; Stefanoudakis D; Shen J; Drakaki A
    World J Urol; 2021 Mar; 39(3):741-749. PubMed ID: 32361873
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data.
    Ronan K; Jordan E; Leonard C; McDermott R
    Ir J Med Sci; 2024 Jun; 193(3):1155-1161. PubMed ID: 37947995
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now.
    Peng J; Sridhar S; Siefker-Radtke AO; Selvarajah S; Jiang DM
    Curr Treat Options Oncol; 2022 Sep; 23(9):1269-1287. PubMed ID: 35962938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.
    Dosne AG; Valade E; Goeyvaerts N; De Porre P; Avadhani A; O'Hagan A; Li LY; Ouellet D; Perez Ruixo JJ
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):151-164. PubMed ID: 34977972
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.
    Kikuchi A; Suzuki T; Nakazawa T; Iizuka M; Nakayama A; Ozawa T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
    Cancer Sci; 2017 Feb; 108(2):236-242. PubMed ID: 27885740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO].
    Rexer H; Ohlmann CH; Gschwend J;
    Urologe A; 2017 Oct; 56(10):1331-1332. PubMed ID: 28779222
    [No Abstract]   [Full Text] [Related]  

  • 59. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma.
    Zengin ZB; Chehrazi-Raffle A; Salgia NJ; Muddasani R; Ali S; Meza L; Pal SK
    Urol Oncol; 2022 Feb; 40(2):25-36. PubMed ID: 34840077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. P4HA2-mediated HIF-1α stabilization promotes erdafitinib-resistance in FGFR3-alteration bladder cancer.
    Li X; Li Y; Liu B; Chen L; Lyu F; Zhang P; He Q; Cheng L; Liu C; Song Y; Xing Y
    FASEB J; 2023 Apr; 37(4):e22840. PubMed ID: 36943397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.